Integrated Biosciences, a biotechnology company using optogenetics, chemistry and AI to discover therapeutics for age-related diseases, has appointed Tony Wu, co-founder of xAI, to its Scientific Advisory Board. Wu played a key role in building Grok, xAI's reasoning and agentic AI model, and scaling the Colossus supercomputer cluster. His expertise in large-scale model training and AI applications to scientific discovery will support Integrated Biosciences' platform, which has demonstrated sixfold improvements in hit rates for senolytic compounds and breakthroughs in virtual staining and biological age inference from microscopy. The appointment strengthens the company's advisory board, which includes experts in ageing biology, drug discovery and a Nobel Prize winner in chemistry. Integrated Biosciences is based in Redwood City, California.

Integrated Biosciences has appointed Daniel J. Anderson as chief scientific officer. Anderson joins from Eikon Therapeutics, where he served as CSO and managed a team of 130 scientists leading discovery and translational research efforts. In his new role, Anderson will oversee scientific strategy and pipeline development at Integrated Biosciences, which combines synthetic biology, chemistry and AI to discover small-molecule therapeutics for age-related diseases. He previously held positions at Recursion Pharmaceuticals, Cleave Biosciences and Genentech, advancing 10 programmes into clinical trials. Max Wilson, co-founder of Integrated Biosciences, has moved to chief technology officer, where he will focus on advancing the company's technology platform, including AI-enabled discovery systems and high-throughput biological screening.

Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics f